title: [Efficacy Analysis of MAC Regimen as Salvage Treatment Protocol for Acute Myeloid Leukemia Patients Older Than 55 Years].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of MAC regimen in the treatment of acute myeloid leukemia(AML) patients older than 55 years.
  
  
  METHODS
  A total of 33 relapsed or non-remission AML patients older than 55 years were enrolled in this research. MAC regimen was given as the salvage treatment. Complete remission rate(CR), partial remission rate(PR), overall survival(OS), relapse-free survival(RFS) and adverse effect were analysed.
  
  
  RESULTS
  CR rate after the salvage therapy with MAC was 51.1%, partial remission (PR) rate was 6.1%, the overall response rate (ORR) was 57.6%, the median OS was 8 months (1.0-66.0 months), the median relapse-free survival (RFS) was 10.1 months (2.3-40.4 months). Mortality related with salvage treatment in 30 days was 9.1%. Low incidence of severe organ damage were found.
  
  
  CONCLUSIONS
  MAC can be used as a relative effective and safe regimen for the salvage treatment of the older AML patients.
authors.affiliation: Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Seiences & Peking Unian Medical College, Tianjin 300020, China.
authors.forename: Xing-Li
authors.initials: XL
authors.lastname: Zhao
authors.affiliation: Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Seiences & Peking Unian Medical College, Tianjin 300020, China.
authors.forename: Shu-Ning
authors.initials: SN
authors.lastname: Wei
authors.affiliation: Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Seiences & Peking Unian Medical College, Tianjin 300020, China.
authors.forename: Kai-Qi
authors.initials: KQ
authors.lastname: Liu
authors.affiliation: Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Seiences & Peking Unian Medical College, Tianjin 300020, China.
authors.forename: Dong
authors.initials: D
authors.lastname: Lin
authors.affiliation: Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Seiences & Peking Unian Medical College, Tianjin 300020, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Wei
authors.affiliation: Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Seiences & Peking Unian Medical College, Tianjin 300020, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Seiences & Peking Unian Medical College, Tianjin 300020, China.
authors.forename: Chun-Lin
authors.initials: CL
authors.lastname: Zhou
authors.affiliation: Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Seiences & Peking Unian Medical College, Tianjin 300020, China.
authors.forename: Bing-Cheng
authors.initials: BC
authors.lastname: Liu
authors.affiliation: Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Seiences & Peking Unian Medical College, Tianjin 300020, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Li
authors.affiliation: Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Seiences & Peking Unian Medical College, Tianjin 300020, China.
authors.forename: Zeng
authors.initials: Z
authors.lastname: Cao
authors.affiliation: Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Seiences & Peking Unian Medical College, Tianjin 300020, China.
authors.forename: Ben-Fa
authors.initials: BF
authors.lastname: Gong
authors.affiliation: Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Seiences & Peking Unian Medical College, Tianjin 300020, China.
authors.forename: Yun-Tao
authors.initials: YT
authors.lastname: Liu
authors.affiliation: Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Seiences & Peking Unian Medical College, Tianjin 300020, China.
authors.forename: Xiao-Yuan
authors.initials: XY
authors.lastname: Gong
authors.affiliation: Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Seiences & Peking Unian Medical College, Tianjin 300020, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
authors.affiliation: Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Seiences & Peking Unian Medical College, Tianjin 300020, China.
authors.forename: Run-Xia
authors.initials: RX
authors.lastname: Gu
authors.affiliation: Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Seiences & Peking Unian Medical College, Tianjin 300020, China.
authors.forename: Guang-Ji
authors.initials: GJ
authors.lastname: Zhang
authors.affiliation: Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Seiences & Peking Unian Medical College, Tianjin 300020, China.
authors.forename: Jian-Xiang
authors.initials: JX
authors.lastname: Wang
authors.affiliation: Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Seiences & Peking Unian Medical College, Tianjin 300020, China. E-mail: miyingch@medmail.com.cn.
authors.forename: Ying-Chang
authors.initials: YC
authors.lastname: Mi
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D002699:Chlorambucil; D003561:Cytarabine; D003609:Dactinomycin; D006801:Humans; D015470:Leukemia, Myeloid, Acute; D008727:Methotrexate; D008875:Middle Aged; D012008:Recurrence; D012074:Remission Induction; D016879:Salvage Therapy
chemical_list: D003561:Cytarabine; D002699:Chlorambucil; D003609:Dactinomycin; D008727:Methotrexate